A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2023-02-16
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 29); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-04 (study day 40); relationship: N
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 42); relationship: not assessed; serious criteria: hospitalization
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-11 (study day 77); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-24 (study day 121); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 130); relationship: not assessed
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-07-04 (study day 131); relationship: not assessed; serious criteria: hospitalization
Data queries
No data queries.